TC BioPharm (Holdings) plc
TCBPDelisted Aug 8, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001872812
TC BioPharm (Holdings) plc was delisted on Aug 8, 2025; its insiders filed their last Form 4 on Jan 11, 2023; 12 institutions reported holding it in 13F filings for Q3 2023, worth $179.6K in total; no superinvestor held it.
13F holders, Q4 2023
Institutional positions in TC BioPharm (Holdings) plc as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
TCBP is no longer listed, and 13F filings after Q3 2023 list far fewer holders. See Q3 2023
- Institutional holders
- 4
- −7 vs. Q3 2023
- Shares held
- 76.9K
- −357.2K (−82.3%) vs. Q3 2023
- Total value
- $243.8K
- +$64.2K (+35.7%) vs. Q3 2023
- New holders
- 2
- 0 more added
- Sold out
- 9
- 2 more reduced
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TCBP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 1 | $34 |
| Q1 2025 | 1 | $34 |
| Q4 2024 | 12 | $34.8K |
| Q3 2024 | 8 | $48.9K |
| Q2 2024 | 8 | $77.0K |
| Q1 2024 | 5 | $42.6K |
| Q4 2023 | 4 | $243.8K |
| Q3 2023 | 12 | $179.6K |
| Q2 2023 | 6 | $380.1K |
| Q1 2023 | 4 | $207.3K |
| Q4 2022 | 2 | $323.8K |
| Q3 2022 | 5 | $141.0K |
| Q2 2022 | 5 | $166.0K |
| Q1 2022 | 8 | $399.0K |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding TC BioPharm (Holdings) plc; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 74,000 | $234.6K | 0.01% | −223,500−75.1% | Reduced |
| Tower Research Capital LLC (TRC) | 2,770 | $8.78K | 0.00% | +2,770 | New |
| JPMorgan Chase & Co | 89 | $282 | 0.00% | +89 | New |
| Wells Fargo & Company | 50 | $159 | 0.00% | −12,950−99.6% | Reduced |
| Csenge Advisory Group | 0 | $0 | 0.00% | −26,000−100.0% | Sold out |
| Cresset Asset Management, LLC | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −13,401−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −13,617−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −13,543−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −11,003−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −3,516−100.0% | Sold out |
| Clear Street LLC | 0 | $0 | 0.00% | −1,323−100.0% | Sold out |
| Modera Wealth Management, LLC | 0 | $0 | 0.00% | −16,244−100.0% | Sold out |
| Steward Financial Group LLC | – | – | – | – | Not filed |